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 Springer Science+Business Media, LLC 2009
We have read with great interest the study performed in
Pakistan by Abbas et al. [1] on the efficacy and safety of a
‘‘rescue’’ therapy to cure Helicobacter pylori infection.
Briefly, following a quadruple therapy including high-dose
esomeprazole, bismuth salts, amoxicillin-clavulanic acid,
and furazolidone, an 81% eradication rate was achieved at
ITT analysis, with a side-effects incidence as high as 50%.
The authors concluded that ‘‘it is reasonably well tolerated
and is an effective second-line regimen’’ and even sug-
gested it could be used as a first-line therapy. We have
some concerns about these conclusions. First, following the
first-line therapy, H. pylori eradication was achieved in
119 (67.6%) out of 176 enrolled patients. Consequently, 57
eradication failure patients were available instead of 52, as
was reported. If all these patients received a second-line
therapy, then both ITT and PP analysis should be accord-
ingly calculated. Second, the reported side-effects
incidence (up to 50%) would appear much higher than that
observed following a simpler, 10-day levofloxacin-based
second-line triple therapy, which is 18% in near 1,000
patients, with an 81% eradication rate [2]. Third, it has
been claimed that drug cost is a cause for concern in
developing countries [1]. However, esomeprazole is the
most expensive proton pump inhibitor, and the dose used
(40 mg b.i.d.) in this study was twice that widely suggested
in the literature [3]. This markedly increased the overall
therapeutic cost of eradication therapy, contrasting one of
the aims of the study. In addition, when bismuth salts are
administered with a high-dose of the proton pump inhibi-
tor, bismuth toxicity may also be a cause for concern, since
very high blood bismuth concentrations within the Hille-
mand alarm levels have been found in 9% of patients
receiving a quadruple therapy, suggesting there should be
more caution in prescribing bismuth salt with proton pump
inhibitors [4]. Finally, some relevant ethical concerns arise
with the use of furazolidone. This is an antibiotic that was
used in the 1980s for parasitic infections, and some studies
described its use in human subjects to treat H. pylori
infection. In the 1990s, studies were published that raised
several concerns about this agent and its potential for
causing tumors. At the same time, the company that made
the agent in the United States (Roberts Pharmaceuticals)
was sold to Shire Pharmaceuticals, and the FDA withdrew
its approval for furazolidone in March 2005. The drug was
ordered removed even from animals as an antibiotic by the
FDA in 2002. The FDA has subsequently sued companies
that illegally imported the drug from Mexico for use in
animals. Simultaneously, the European Medicinal Agency
(EMEA; the equivalent of the FDA in the European Union)
banned the drug in Europe. Although the drug continues to
be available in some developing countries such as Iran,
Pakistan, India, Mexico, and Brazil, a number of public and
press campaigns from concerned individuals have urged
governments to ban the drug in some of those countries.
Therefore, can we consider a therapy including furazoli-
done as the authors declared as ‘‘safe’’? Although it has
been stated that the study was approved by the Ethical
Committee, were patients informed of the possible geno-
toxic and carcinogenetic effects [5, 6] for which
furazolidone is not currently approved by the FDA and
EMEA?
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Reply
To the Editor,
We would like to thank Dr. Francesco, et al. for criti-
cally reading our article and take this opportunity to
address their concerns. We felt that we should not include
those patients in the analysis who could not be enrolled for
the new regimen and did not receive even a single dose.
Side-effects reported were mild and no one discontinued
the treatment. The cost of esomeprazole is at par with other
proton pump inhibitors in our country. We are aware of the
concerns about the safety of furazolidone and bismuth
compounds. The metabolites of nitrofuran drugs may have
some carcinogenic effect in rodents, however, furazolidone
has been extensively used and is still being used in humans
[7–9] and we find no reports of such side-effects. We find a
similar dilemma against nitroimidazoles in literature. In
spite of the mutagenic, genotoxic, and carcinogenic activity
of metronidazole in animal models [10, 11], the drug is still
being used all over the world, not only as an anti-H. pylori
agent but also for many other indications. There are more
than 100 papers related to the use of nitrofuran drugs for
H. pylori treatment [9]. In fact, the furan compounds are
also being researched as anticancer agents [12]. Similarly,
bismuth compounds are still a part of the alternate therapies
for patients who fail to respond to classical triple therapy
and are considered safe and well-tolerated agents [13].
However, we agree that in such trials there is a need to
study the long-term safety of the compounds used.
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